Danaher (DHR)
(Delayed Data from NYSE)
$236.08 USD
+0.57 (0.24%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $236.25 +0.17 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Danaher Corporation [DHR]
Reports for Purchase
Showing records 161 - 180 ( 496 total )
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Omicron: Life Science Tools Firms Likely Seeing Softer Landing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Company: Danaher Corporation
Industry: Diversified Operations
Beats and More Coming - Positive for RGEN, WST, MRVI
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Beats Our Street High Estimates; Bookings and COVID "Durable"
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Company: Danaher Corporation
Industry: Diversified Operations
Life Science Tools - Vaccine, Bioproduction, mRNA, Cell & Gene Therapy and M&A: 2H21 Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Company: Danaher Corporation
Industry: Diversified Operations
Comprehensive Technical and Fundamental Analysis for DHR.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Comprehensive Technical and Fundamental Analysis for DHR.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Provider: Zacks Investment Research
Analyst: Research Department
Company: Danaher Corporation
Industry: Diversified Operations
Aldevron Acquisition: Next Move on Bioproduction Chessboard and $9.6B Validation of mRNA and CGT Market Potential for Peers
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department